CREXONT® (IPX203, ER CD-LD) Super-responders: Enhanced Symptom Control in Parkinson’s Disease (P3-17.003)

Simon Allard; Ghazal Banisadr; Stanley Fisher; Peter LeWitt

doi:10.1212/wnl.0000000000215178

June 9, 2026Neurology

CREXONT® (IPX203, ER CD-LD) Super-responders: Enhanced Symptom Control in Parkinson’s Disease (P3-17.003)

View at Publisher

Ask AI

Bookmark

Share

Key Points

The research assesses whether CREXONT® (IPX203) leads to better clinical outcomes in patients with poor absorption of conventional treatments.
Evaluated clinical improvement in patients with poor response to IR CD-LD after switching to CREXONT®.
Administered CREXONT® and monitored symptom control in Parkinson’s disease patients.
Patients switching to CREXONT®showed greater clinical improvement in symptoms compared to previous treatment.

Implication

Shows enhanced symptom control in patients with Parkinson’s disease after switching to CREXONT®.

Abstract

To assess if CREXONT® (IPX203) improves absorption by evaluating whether patients with poor IR CD-LD response show greater clinical improvement after switching to CREXONT.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Allard et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf403faef96ed7f0565b9 https://doi.org/10.1212/wnl.0000000000215178

View at Publisher

Ask AI

Bookmark

Share

CREXONT® (IPX203, ER CD-LD) Super-responders: Enhanced Symptom Control in Parkinson’s Disease (P3-17.003)

Key Points

Implication

Abstract

Discussion

Cite This Study

CREXONT® (IPX203, ER CD-LD) Super-responders: Enhanced Symptom Control in Parkinson’s Disease (P3-17.003)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Neurology

Keep reading

More related papers

More from Neurology